Moreover, a phase II clinical study testing a recombinant TNF receptor 1 (TNFR1) immunoglobulin fusion protein neutralizing TNF (lenercept) in patients with multiple sclerosis (MS) had to be halted due to exacerbation of symptoms when compared to placebo-treated MS patients [7]. This evidence concerns the gene TNF and multiple sclerosis.